体外研究 (In Vitro) |
NEO212 (5-50 μM; 24 h) 可在非细胞毒性剂量下可逆性抑制间质型 USC02 胶质瘤干细胞的迁移,其迁移抑制活性在 24 h 后仍保持稳定,且与其短效的细胞毒性 DNA 烷化作用无关。 NEO212 (15 μM; 16 h) 可显著降低间质型 USC02 胶质瘤干细胞及新鲜分离的患者来源胶质瘤细胞的侵袭能力。 NEO212 (3-15 μM) 可降低间质型 USC02 和前神经型 USC04 胶质瘤干细胞中侵袭相关蛋白 MMP2 和 MMP9 的表达水平。 NEO212 (3-15 μM) 可选择性阻断间质型 USC02 和原神经型 USC04 胶质瘤干细胞中 FAK/Src 信号通路及其下游激酶的激活,其作用机制不同于 TMZ 的非特异性蛋白质合成抑制作用。 NEO212 (3-15 μM) 可通过调控关键 EMT 相关基因逆转间质型 USC02 胶质瘤干细胞的 EMT 表型,并促进神经元前体型 USC04 胶质瘤干细胞向上皮样特征转变。 NEO212 (25-300 μM; 48 h) 可呈剂量依赖性地抑制 A2780、SK-O-V3 和 OVCAR-3 人卵巢癌细胞的活力,且其效力强于 TMZ、POH 或二者的联合用药。 NEO212 (100 μM; 48 h) 可强效抑制 A2780、SK-O-V3 和 OVCAR-3 人卵巢癌细胞的集落形成,其效力优于 TMZ、POH 或二者联用。 NEO212 (100 μM; 48 h) 可诱导 A2780、SK-O-V3 和 OVCAR-3 人卵巢癌细胞发生 G2/M 期细胞周期阻滞。 NEO212 (100 μM; 48 h) 可在人卵巢癌细胞 A2780 和 SK-O-V3 中诱导强烈的 DNA 损伤,这一点可通过 ATM、CHEK1、CHEK2 和 H2AFX 的磷酸化水平升高得到证实。 NEO212 (100 μM; 48 h) 主要通过半胱天冬酶依赖的线粒体途径诱导 A2780、SK-O-V3 和 OVCAR-3 人卵巢癌细胞发生凋亡,同时存在少量半胱天冬酶非依赖的作用组分。 NEO212 (100 μM; 48 h) 可诱导 A2780 和 SK-O-V3 人卵巢癌细胞发生线粒体分裂及形态损伤,表现为线粒体长宽比降低、内部基质变形。 NEO212 (100 μM; 48 h) 可诱导人卵巢癌细胞 A2780 和 SK-O-V3 发生线粒体功能障碍,表现为线粒体跨膜电位显著降低。 NEO212 (100 μM; 48 h) 可诱导人卵巢癌细胞 A2780 和 SK-O-V3 中自噬体积累,但不会促进过度的自噬降解。 NEO212 (100 μM; 48 h) 通过损伤溶酶体功能并减少自噬体-溶酶体融合,阻断 A2780 和 SK-O-V3 人卵巢癌细胞中的自噬流。 NEO212 (100 μM; 48 h) 可通过上调 AKT 和 ERK 的磷酸化水平,抑制人卵巢癌细胞 A2780 和 SK-O-V3 中 TFEB 的核转位,进而导致溶酶体功能受损。 NEO212 (1-100 μM; 4-5 days) 可强效降低犬源 CLBL1 细胞、犬源 CLL1390 细胞、人源 HL60 细胞、人源 THP1 细胞、人源 Raji 细胞和人源 U937 细胞的活力,其 IC50 值范围为 1.7 至 42 μM;且与 O6BG 联合处理可增强其对 MGMT 高表达 CLL1390 细胞的细胞毒性。 NEO212 (1-70 μM; 3-7 days) 可诱导犬源 CLBL1 细胞、犬源 CLL1390 细胞、人源 HL60 细胞、人源 Raji 细胞和人源 U937 细胞发生细胞凋亡,且在耐 TMZ 的 CLL1390 细胞中仍具有活性。 NEO212 (0-100 μM; 5 days) 在体外可强效抑制人 AML 细胞系 U937、6D10、HL60、KG1 和 THP1 的活性,其 IC50 值范围为 ≤ 5 μM 至 50 μM,且在 MGMT 阳性 AML 细胞中的效果优于 TMZ。 NEO212 (50-100 μM; 16-32 h) 以时间和浓度依赖性方式下调人 THP1 和 HL60 急性髓系白血病 (AML) 细胞中的 MGMT 蛋白水平,而 TMZ 不会改变 MGMT 水平。 NEO212 (30 μM; 1-5 days) 可刺激人源阿糖胞苷耐药性 6D10 AML 细胞中巨噬细胞分化标记基因的表达。 NEO212 (10-100 μM; 3-5 days) 可在体外显著上调人 U937、6D10、THP1 和 HL60 AML 细胞中 CD11b mRNA 的水平,该效应无法由等摩尔浓度的 TMZ 与 POH 混合物模拟。 NEO212 (10-100 μM; 3-5 days) 可在体外上调人 U937、6D10、HL60 和 THP1 AML 细胞的细胞表面 CD11b 蛋白水平,该效应无法被 TMZ、POH 或它们的等摩尔混合物复制。
Cell Migration Assay
| Cell Line: |
mesenchymal patient-derived glioma stem cells (USC02) |
| Concentration: |
5, 15, 25 and 50 μM |
| Incubation Time: |
24 h |
| Result: |
Showed dose-dependent impaired migration compared to vehicle-treated cells. Caused no significant difference in viable cell count compared to vehicle controls after 24 h treatment. Regained migratory ability after 24 h treatment followed by 48 h drug-free recovery, showing significantly larger wound area than cells treated continuously for 72 h.
|
Cell Invasion Assay
| Cell Line: |
mesenchymal patient-derived glioma stem cells (USC02), freshly derived patient glioma cells |
| Concentration: |
15 μM |
| Incubation Time: |
16 h |
| Result: |
Significantly decreased the invasion rate of USC02 cells, while TMZ and/or perillyl alcohol showed no significant effects. Decreased invasion capacity in all five tested samples of freshly derived patient glioma cells, despite varying baseline invasion rates. |
Cell Viability Assay
| Cell Line: |
A2780, SK-O-V3, OVCAR-3 human ovarian cancer cell lines |
| Concentration: |
25, 50, 100, 150, 200, 300 μM |
| Incubation Time: |
48 h |
| Result: |
Inhibited cell viability in a dose-dependent manner across all three cell lines, with stronger inhibitory effects than its individual constituents (TMZ, POH) and their combination. |
Cell Cycle Analysis
| Cell Line: |
A2780, SK-O-V3, OVCAR-3 human ovarian cancer cell lines |
| Concentration: |
100 μM |
| Incubation Time: |
48 h |
| Result: |
Increased the population of cells in the G2/M phase and decreased the population in the G1 phase across all three cell lines, indicating G2/M arrest. |
Western Blot Analysis
| Cell Line: |
A2780, SK-O-V3 human ovarian cancer cell lines |
| Concentration: |
100 μM |
| Incubation Time: |
48 h |
| Result: |
Induced higher levels of phosphorylated ATM (Ser1981), phosphorylated CHEK1 (Ser345), phosphorylated CHEK2 (Thr68), and phosphorylated H2AFX (Ser139) compared to TMZ, POH, or their combination, indicating stronger DNA damage. |
Apoptosis Analysis
| Cell Line: |
A2780, SK-O-V3, OVCAR-3 human ovarian cancer cell lines |
| Concentration: |
100 μM; 100 μM (with concurrent 20 μM Z-VAD-FMK or 10 μM Ac-LEHD-FMK) |
| Incubation Time: |
48 h; 48 h |
| Result: |
Induced significantly higher levels of apoptotic and dead cells compared to TMZ, POH, or their combination in all three cell lines. Both Z-VAD-FMK and Ac-LEHD-FMK significantly reduced NEO212-induced apoptosis, but did not completely block it. |
Cell Cytotoxicity Assay
| Cell Line: |
human acute myeloid leukemia (AML) cell lines U937, 6D10, HL60, KG1, THP1 |
| Concentration: |
0-10 μM (U937, 6D10); 0-100 μM (HL60, KG1, THP1) |
| Incubation Time: |
5 days |
| Result: |
Potently inhibited viability of all tested AML cell lines, with IC50 values of ≤ 5 μM for U937, 6D10, HL60, and KG1 cells; THP1 cells had an IC50 around 50 μM. Was far more potent than TMZ in MGMT-positive HL60, KG1, and THP1 cells, and equally potent as TMZ in MGMT-negative U937 and 6D10 cells. Did not have its cytotoxic potency mimicked by an equimolar mix of TMZ and POH. |
Western Blot Analysis
| Cell Line: |
human AML cell lines THP1, HL60 |
| Concentration: |
50, 75, 100 μM (24 h incubation); 80 μM (16, 24, 32 h incubation); 60, 80 μM (24 h incubation) |
| Incubation Time: |
16 h, 24 h, 32 h |
| Result: |
Caused striking down-regulation of MGMT protein levels in THP1 and HL60 cells, with the effect detectable as early as 16 h after treatment with 50 μM NEO212, and more pronounced in THP1 cells than HL60 cells. Showed no effect on MGMT protein levels when compared to TMZ treatment at concentrations up to 200 μM. |
Real Time qPCR
| Cell Line: |
human AML cell lines U937, 6D10, THP1, HL60 |
| Concentration: |
10 μM (U937, 6D10); 50 μM (THP1); 75, 100 μM (HL60) |
| Incubation Time: |
3, 5 days (U937, 6D10, THP1); 5 days (HL60) |
| Result: |
Caused significant induction of CD11b transcript in all tested AML cell lines, with increases observed across different concentrations and time points. Did not have its CD11b expression induction mimicked by an equimolar mix of TMZ and POH, while the positive control TPA did. |
|
体内研究 (In Vivo) |
NEO212 (5-25 mg/kg;皮下注射;给药 5 天、停药 2 天循环给药共 35 天) 可显著延长胶质母细胞瘤原位小鼠模型的生存期、延缓肿瘤进展并减少胶质瘤干细胞侵袭。 NEO212 (25 mg/kg;每日一次;共 15 天) 在体内展现出强效的抗卵巢癌活性,可将肿瘤生长抑制至第 1 天的终末体积倍数约为 10,诱导肿瘤坏死与凋亡,且在 BALB/c 裸鼠中未表现出显著的全身毒性。 NEO212 (25 mg/kg;口服;每个周期连续 5 天每日 1 次;共 2 个周期) 可显著延长携带人源或犬源白血病/淋巴瘤异种移植物的小鼠的生存期,在两个模型中 200 天时的存活率达 100%,疗效优于 TMZ。 NEO212 (25 mg/kg;口服;每周期连续 5 天每日 1 次;共 3 个周期) 处理可使小鼠获得 > 300 天的 100% 存活率,对小鼠体内耐阿糖胞苷 (AraC) 的 AML 表现出明确的治愈活性。 NEO212 (25 mg/kg;口服;每个周期连续 5 天每日一次;共 2 个周期) 处理使小鼠获得了超过 300 天的 100%存活率,对 TMZ 耐药的 AML 表现出明确的治愈活性。 NEO212 (100-200 mg/kg;口服;每日 1 次;连续 5 天) 在大鼠中具有良好的耐受性,当给药剂量高达 200 mg/kg、连续给药 5 天时,未观察到严重骨髓抑制或死亡情况。
| Animal Model: |
NOD/SCID (8-10 week old male; intracranial implantation of luciferase-labeled mesenchymal USC02 glioma stem cells) |
| Dosage: |
5 mg/kg; 25 mg/kg |
| Administration: |
s.c.; 5 days on, 2 days off cycles for 35 days |
| Result: |
Prolonged mouse survival significantly. Delayed tumor progression highly significantly. Reduced invasion of human tumor cells into normal brain parenchyma, showing a clear distinct border between tumor and normal brain. |
| Animal Model: |
BALB/c nude (female, 4-6 weeks of age, subcutaneous inoculation of 5×106 SK-O-V3 cells) |
| Dosage: |
25 mg/kg |
| Administration: |
daily; 15 days |
| Result: |
Reduced final fold tumor volume relative to day 1 to ~10, compared to ~40 in DMSO control. Induced necrotic foci in tumors via H&E staining. Increased cleaved caspase-3 staining, indicating enhanced apoptosis. Showed no statistically significant difference in body weight compared to control. Caused no morphological/histological changes in major organs (heart, liver, spleen, lung, kidney). |
| Animal Model: |
NOD-SCID or NSG-SGM3 (female, 6-8 weeks old, implanted with human or canine leukaemia/lymphoma cells) |
| Dosage: |
25 mg/kg |
| Administration: |
p.o.; once daily for 5 consecutive days per cycle; two cycles total |
| Result: |
Prolonged survival significantly in all five tumour models. Achieved 100% survival at 200 days in human HL60 leukaemia and canine CLL1390 leukaemia models. Showed significantly prolonged survival compared to vehicle controls in human U937 leukaemia model. Extended survival significantly longer than vehicle and TMZ-treated mice in human Raji lymphoma model. Extended survival significantly longer than vehicle and TMZ-treated mice in canine CLBL1 lymphoma model. Extended survival significantly longer than vehicle and TMZ-treated mice in canine CLL1390 leukaemia model. |
| Animal Model: |
NOD-SCID (female, 6-8 weeks old, injected intraperitoneally with 5×104 MGMT-negative, AraC-resistant 6D10 AML cells) |
| Dosage: |
25 mg/kg |
| Administration: |
p.o.; once daily for 5 consecutive days per cycle; 3 total cycles |
| Result: |
Ensured 100% of treated mice survived > 300 days without signs of disease. Rendered human AML cells undetectable in blood via sensitive Alu sequence PCR assay. |
| Animal Model: |
NOD-SCID (female, 6-8 weeks old, injected intraperitoneally with 5×104 MGMT-positive, TMZ-resistant HL60 AML cells) |
| Dosage: |
25 mg/kg |
| Administration: |
p.o.; once daily for 5 consecutive days per cycle; 2 total cycles |
| Result: |
Ensured 100% of treated mice survived > 300 days without signs of disease. Rendered human AML cells undetectable in blood via sensitive Alu sequence PCR assay. |
|